What are the indications, recommended adult dosing, contraindications, monitoring parameters, and common adverse effects of spironolactone?

Spironolactone: Indications, Dosing, Contraindications, Monitoring, and Adverse Effects

Spironolactone is a potassium-sparing aldosterone antagonist with proven mortality benefit in heart failure with reduced ejection fraction (HFrEF), established efficacy in resistant hypertension, and off-label effectiveness for acne in women, but its use demands rigorous potassium and renal function monitoring to prevent life-threatening hyperkalemia.

Primary Indications

Heart Failure with Reduced Ejection Fraction (HFrEF)

• LVEF ≤35% with NYHA class III-IV symptoms (moderate to severe heart failure) on optimal therapy with a β-blocker and an ACE inhibitor or ARB (but not both an ACEI and ARB together) 1
• The RALES trial demonstrated a 30% relative risk reduction in mortality and 35% reduction in heart failure hospitalizations when spironolactone was added to conventional therapy 1
• Number needed to treat (NNT) = 9 for 2 years to prevent one death in severe heart failure 1

Essential Hypertension

• Particularly effective in resistant hypertension (hypertension uncontrolled on ≥3 medications) 1
• Reduces systolic blood pressure by approximately 20 mmHg and diastolic by 6.75 mmHg at doses of 100-500 mg/day 2

Edema Associated with Cirrhosis

• Initiate therapy in a hospital setting with slow titration in cirrhotic patients 3
• Effective as sole diuretic agent when administered for at least 5 days before dose escalation 3

Primary Hyperaldosteronism

• Doses of 100-400 mg daily for surgical preparation or long-term maintenance in patients unsuitable for surgery 3

Off-Label: Acne Vulgaris in Women

• Effective for all types of acne (facial and truncal) through anti-androgenic effects on sebocytes 1, 4
• Not limited to adult women or lower-face distribution—effective across age groups 1

Recommended Adult Dosing

Heart Failure (HFrEF)

Initiation:

• Baseline requirements: Serum potassium ≤5.0 mEq/L, eGFR >50 mL/min/1.73 m² 3
• Starting dose: 25 mg once daily 1, 3
• For eGFR 30-50 mL/min/1.73 m²: Consider 25 mg every other day 3
• Check renal function and electrolytes at 1 and 4 weeks after initiation 1

Titration:

• After 4-8 weeks, increase to target dose of 50 mg once daily if tolerated 1
• Do not increase if worsening renal function or hyperkalemia develops 1
• Recheck labs at 1 and 4 weeks after dose increase 1

Maintenance monitoring:

• Check potassium and creatinine at 1,2,3, and 6 months, then every 6 months 1

Essential Hypertension

• Initial dose: 25-100 mg daily (single or divided doses) 3
• Titrate at 2-week intervals; doses >100 mg/day provide minimal additional benefit 3

Edema (Cirrhosis)

• Initial dose: 100 mg daily (range 25-200 mg), single or divided doses 3
• Administer for at least 5 days before increasing dose 3

Acne (Off-Label)

• Starting dose: 100 mg daily in the evening 1, 4
• Doses up to 200 mg/day can be used, but side effects increase with higher doses 1
• Several months of treatment required for full effectiveness 1

Absolute Contraindications

• Hyperkalemia (baseline potassium ≥5.0 mEq/L) 3
• Addison's disease 3
• Concomitant use of eplerenone 3
• Severe renal impairment: eGFR <30 mL/min/1.73 m² 1
• Baseline creatinine >2.5 mg/dL in men or >2.0 mg/dL in women 1
• Pregnancy (Category C; risk of feminization of male fetus in animal studies) 1

Critical Monitoring Parameters

Baseline Assessment

• Serum potassium (must be ≤5.0 mEq/L) 1, 3
• Serum creatinine and eGFR 1
• Blood urea nitrogen 1

Early Monitoring (High-Risk Period)

• Check potassium and renal function at 3 days, 1 week, then monthly for first 3 months 1
• More frequent monitoring if:
  • Concomitant high-dose ACE inhibitors (captopril ≥75 mg, enalapril/lisinopril ≥10 mg daily) 1
  • Baseline renal impairment 1
  • Elderly patients 1
  • Diabetes mellitus (especially insulin-requiring) 1

Long-Term Monitoring

• Serum electrolytes (potassium, sodium, magnesium, calcium) 3
• Renal function (creatinine, eGFR) 3
• Uric acid and blood glucose periodically 3

Potassium Monitoring NOT Required

• Young, healthy women treated for acne without heart disease, hypertension, renal disease, or interacting medications 1
• Safe even with concomitant drospirenone-containing oral contraceptives 1

Common and Serious Adverse Effects

Hyperkalemia (Most Dangerous)

• Incidence: 13-24% at 25-50 mg doses in real-world practice (vs. 2% in RALES trial) 1
• Risk factors: Renal dysfunction, diabetes, elderly, concomitant ACE inhibitors/ARBs, NSAIDs, potassium supplements 1
• Management algorithm:
  • Potassium 5.5-6.0 mEq/L: Halve dose (e.g., 25 mg every other day), monitor closely 1, 5
  • Potassium ≥6.0 mEq/L: Stop immediately, treat hyperkalemia, monitor closely 1, 5

Worsening Renal Function

• Creatinine 220-310 µmol/L (2.5-3.5 mg/dL): Halve dose, monitor closely 1, 5
• Creatinine >310 µmol/L (>3.5 mg/dL): Stop immediately, evaluate for renal-specific therapy 1, 5

Gynecomastia and Breast Effects

• Incidence: 9-10% in men (dose-dependent) 1, 3
• Onset varies from 1-2 months to >1 year 3
• Usually reversible upon discontinuation 3
• Management: Switch to eplerenone if breast tenderness/enlargement occurs 1

Menstrual Irregularities

• Incidence: 15-30% (dose-dependent) 1
• Relative risk 4.12 at 200 mg/day vs. lower doses 1
• Prevention: Concomitant combined oral contraceptive or hormonal IUD 1

Other Common Effects (>10%)

• Headache 1
• Diarrhea 1
• Fatigue 1
• Decreased libido 1

Less Common Effects (1-5%)

• Breast tenderness (3-5%) 1
• Dizziness (3-4%) 1
• Nausea (2-4%) 1
• Polyuria (1-2%) 1

Metabolic Abnormalities

• Hyponatremia, hypomagnesemia, hypocalcemia, hypochloremic alkalosis 3
• Hyperglycemia 3
• Asymptomatic hyperuricemia (rarely precipitates gout) 3

Critical Drug Interactions

Avoid or Use with Extreme Caution

• ACE inhibitors + ARBs + spironolactone: Triple combination not adequately studied and cannot be recommended 1
• NSAIDs and COX-2 inhibitors: Increase hyperkalemia risk, worsen heart failure symptoms—avoid or withdraw 1
• Potassium supplements: Discontinue or reduce before initiating spironolactone 1
• Other potassium-sparing diuretics 1
• Potent CYP3A4 inhibitors 1

Increased Hyperkalemia Risk

• High-dose ACE inhibitors (captopril ≥75 mg, enalapril/lisinopril ≥10 mg daily) 1
• Angiotensin receptor blockers 1
• Renin inhibitor aliskiren 1

Clinical Pitfalls and How to Avoid Them

Real-World Hyperkalemia Risk

• Ontario population study: After RALES publication, spironolactone prescriptions tripled, hyperkalemia hospitalizations increased from 2.4 to 11 per 1000, and associated mortality rose from 0.3 to 2 per 1000 1
• Lesson: Clinical trial populations are highly selected; toxicity increases dramatically in general practice 1

Do Not Discontinue Prematurely

• Mild hyperkalemia (5.0-5.5 mEq/L): Do not permanently stop—attempt dose reduction and address reversible causes first 5
• Spironolactone retains mortality/morbidity benefits even when potassium exceeds 5.5 mEq/L per RALES and EMPHASIS-HF secondary analyses 5

Volume Depletion Risk

• Temporary hold during acute diarrhea or dehydration to prevent hyperkalemia 1, 5
• Excessive diuresis can cause symptomatic hypotension and worsening renal function 3

Potassium Binders as Adjunct

• Patiromer and sodium zirconium cyclosilicate enable continued RAAS inhibitor therapy in hyperkalemic patients 1
• Allow up-titration to target spironolactone doses while maintaining normokalemia 1

Evaluate Alternative Causes

• Do not assume hyperkalemia is always drug-related—assess for acute heart failure decompensation or progressive kidney disease 5

Cancer Risk: Black Box Warning Context

• FDA black box warning based on animal studies at doses >100× clinical use 1
• Multiple large cohort studies with >30 million person-years of follow-up show no confirmed cancer risk in humans at typical clinical doses 1